Durect corp

Financial Times Close. Search the FT Search. Show more World link World.

DURECT harnesses epigenetic modulation to treat serious and life-threatening conditions, including acute organ injury and cancer. Many types of acute organ injuries and cancers are associated with dysregulation of the epigenome, such as DNA methylation. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth. Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies. Brown, President and Chief. Unlocking the potential of epigenetic therapeutics to revolutionize medicine. Epigenetic Modulation.

Durect corp

.

Am J Gastroenterol.

.

Brown , D. In conjunction with teams of experienced chemists and biologists, our research and development team have designed new chemical entities NCE that are now in preclinical development for multiple oncology indications. With this achievement, DURECT is advancing its mission to be a global leader in the emerging field of epigenetic medicine. Earnings Conference Call We will host a conference call and webcast today at p. Pacific Time to discuss second quarter results and provide a corporate update:. Wednesday, August 9 p. Participants can use guest dial-in numbers above to reach an operator or they can click the Call me TM link for instant telephone access to the event dial-out.

Durect corp

The pre-funded warrants and the accompanying warrants will be immediately exercisable. The pre-funded warrants do not expire and the accompanying warrants will expire five years from the date of issuance. The closing of the Offering is expected to occur on or about February 8, , subject to customary closing conditions. DURECT intends to use the net proceeds of the Offering for general corporate purposes, which may include clinical trials, research and development activities, capital expenditures, selling, general and administrative costs, facilities expansion, and to meet working capital needs. The Offering is being made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. The prospectus supplement and the accompanying prospectus relating to, and describing the terms of, the Offering will be filed with the SEC. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of , relating to: the Offering, statements regarding the completion of the Offering and the expected use of proceeds from the Offering, Fast Track Designation of larsucosterol, the potential to develop larsucosterol for AH, NASH or other indications, the commercialization of POSIMIR by Innocoll, and the potential benefits, if any, of our product candidates.

Marisa tomei breast

Health Care Pharmaceuticals and Biotechnology. Join our highly experienced, talented, and collaborative team as we strive to improve the course of human medicine with novel epigenetic therapies. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. It does not store any personal data. The cookie is used to store the user consent for the cookies in the category "Analytics". Add to Your Watchlists New watchlist. Show more Companies link Companies. This cookie, set by Cloudflare, is used to support Cloudflare Bot Management. Make up to three selections, then save. Cookie Duration Description c 6 months 2 days This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services. The emerging role of epigenetics in human autoimmune disorders. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth. Partner With Us. But opting out of some of these cookies may have an effect on your browsing experience.

Brown , D. We look forward to entering discussions with the U.

This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services. The emerging role of epigenetics in human autoimmune disorders. Short lived cookies used by Motomo Analytics to temporarily store data for the visit. All content on FT. The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. Alcohol-Associated Hepatitis AH. There is vast potential for epigenetic therapies to address the underlying pathophysiology by mitigating epigenomic dysregulation and helping to improve cellular function or suppress tumor growth. Cancel Continue. Add to Your Portfolio New portfolio. Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. Explore the Power of Epigenetic Therapy. Epigenetic dysregulation in cardiovascular aging and disease. But opting out of some of these cookies may have an effect on your browsing experience. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website.